The vaccine was administered in 2 doses in 4 weeks. Efficacy In September 2021,<unk>  announced Phase III results showing 67.2% efficacy against all cases of COVID-19 of any degree of severity, 83.7% efficacy against moderate-to-severe disease, and 100% against hospitalisation and severe cases. Additionally, the vaccine was 79% effective against all cases of Delta. Of the 207 cases found during the trials, 52 were from the vaccinated group and 155 from the placebo group. These Phase II/III results have been published in the Lancet. Clover expects to submit its Phase III results for approval by the World Health Organization, European Medicines Agency, and China's NMPA in the fourth quarter of 2021. Efficacy against variants In Phase III trials,<unk>  showed efficacy of 81.7% for moderate-to-severe cases of COVID-19 caused by Delta, 91.8% for Gamma, and 58.6% for Mu. 56 Delta cases, 37 Mu cases, and 13 Gamma cases were recorded during the trials.
SCB-2019
HPTN 052
TIME-ITEM
DCAP-BTLS
SWAP-200
STAR*D
COMLEX-USA
WebPT